Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prescription savings may look simple on the GoodRx app, but the company’s disclosures tell a deeper story of PBM economics, subscription growth, and regulatory scrutiny. If you came searching for “GoodRx SEC filings explained simply” or wondered, “Where can I find the GoodRx annual report 10-K simplified?”, you’re in the right place. Stock Titan’s AI reads each page—whether a 300-page 10-K or a same-day 8-K—and surfaces what matters: PBM concentration risk, monthly active consumer trends, and the real cost of prescription transactions.
Use our dashboard to jump straight into GoodRx quarterly earnings report 10-Q filing summaries, monitor GoodRx insider trading Form 4 transactions, and receive GoodRx Form 4 insider transactions real-time alerts. Our technology converts dense footnotes into plain language, so understanding GoodRx SEC documents with AI feels intuitive, not intimidating. Curious about executive pay? The GoodRx proxy statement executive compensation section is distilled into key figures and policy changes. Need context on sudden announcements? Check the GoodRx 8-K material events explained card for instant clarity.
Every filing type is covered and updated the moment EDGAR posts it—10-Ks, 10-Qs, 8-Ks, DEF 14As, S-8s, even Section 16 reports. Investors rely on our AI-powered summaries to perform GoodRx earnings report filing analysis, trace GoodRx executive stock transactions Form 4, and benchmark telehealth revenue streams without wading through legalese. Whether you’re tracking margin trends or validating insider purchase signals, Stock Titan equips you with concise insights, real-time data, and direct links to the source documents so you can act decisively.
GoodRx Holdings, Inc. disclosed that its board approved retention bonus letter agreements for Chief Executive Officer and President Wendy Barnes and Chief Financial Officer and Treasurer Chris McGinnis on December 9, 2025. Through these agreements, Ms. Barnes is eligible for a cash retention bonus of $2,000,000 and Mr. McGinnis for $1,000,000, each payable within 15 days after signing.
The bonuses must be repaid if employment ends either by the executive without "good reason" or by the company for "cause": 100% of the after-tax bonus if termination occurs on or before December 31, 2026, or 50% if termination occurs between January 1, 2027 and December 31, 2027. In exchange, both executives will forfeit any payment under the company’s 2025 executive bonus plan and any other 2025 annual cash incentive or discretionary bonus program. The full agreements are filed as Exhibits 10.1 and 10.2.
GoodRx Holdings, Inc. officer Romin Nabiey, the Chief Accounting Officer, reported equity transactions dated December 8, 2025. He acquired 10,200 and 2,232 shares of Class A common stock through the vesting and settlement of restricted stock units and disposed of 3,650 and 799 shares at $2.71 per share.
After these transactions, Nabiey directly beneficially owns 165,475 shares of Class A common stock. He also continues to hold restricted stock units representing 30,603 and 20,091 underlying shares, which vest 6.25% initially and then in approximately equal quarterly installments over 15 quarters starting on December 8, 2022 and June 8, 2024, respectively.
GoodRx Holdings, Inc. (GDRX) Chief Accounting Officer Romin Nabiey reported equity award activity on 11/15/2025. He acquired 4,804 shares of Class A common stock upon the vesting and settlement of restricted stock units and then disposed of 1,719 shares at $2.97 per share, typically used to cover taxes. Following these transactions, he directly held 156,492 Class A shares.
The underlying restricted stock unit grant covers 4,804 shares. It vests as to 6.25% of the underlying shares on May 15, 2025, with the remaining 93.75% vesting in approximately equal quarterly installments over the next 15 quarters.
GoodRx Holdings (GDRX) reported an insider transaction by Chief Accounting Officer Romin Nabiey on 11/08/2025. Restricted stock units converted into 12,662 shares of Class A common stock (code M). To cover taxes, 4,531 shares were withheld at $3.11 per share (code F). Following these transactions, Nabiey directly owns 153,407 Class A shares. The filing also shows 75,977 RSUs remaining beneficially owned after the reported activity. Each RSU represents the right to receive one share, with vesting that began on August 8, 2023 and continues in approximately equal quarterly installments thereafter.
GoodRx Holdings, Inc. (GDRX)11/08/2025, 21,691 shares of Class A common stock were acquired via the conversion of deferred stock units (transaction code M).
After the transaction, the director beneficially owned 111,025 shares directly and held 43,384 deferred stock units. The filing notes the award vested as to one-third on November 8, 2025, and that deferred stock units will settle upon specified events, including December 31, 2029 or separation from service.
GoodRx Holdings, Inc. reported Q3 revenue of $196.0 million, up slightly year over year, with operating income of $14.6 million and net income of $1.1 million versus $4.0 million a year ago. For the first nine months, revenue was $602.1 million and net income was $25.0 million. Diluted EPS was $0.00 for the quarter and $0.07 year to date. Cash and equivalents were $273.5 million, and term loan principal was $496.3 million.
The revenue mix shifted: prescription transactions were $127.3 million (vs. $140.4 million), pharma manufacturer solutions rose to $43.4 million (vs. $28.1 million), subscriptions were $20.7 million (vs. $21.3 million), and other revenue was $4.6 million (vs. $5.4 million). Monthly Active Consumers were 5.4 million (vs. 6.5 million). Subscription plans were 671,000. The company repurchased 46.9 million shares year to date for $208.9 million, with $81.4 million remaining under the authorization.
Transactions included acquiring VCRx for $30.0 million and, subsequent to quarter-end, ScriptDrop for $13.5 million. Legal accruals included $25.0 million related to an NDCA class action settlement (subject to court approval) and $5.5 million for indemnification. Management estimates a $35.0–$40.0 million 2025 impact to prescription transactions revenue from retail pharmacy and PBM changes and an integrated savings program volume reduction.
GoodRx Holdings, Inc. announced its financial results for the three and nine months ended September 30, 2025. The company furnished a press release as Exhibit 99.1 to provide details.
The information under Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated.
GoodRx (GDRX) director Trevor Bezdek reported equity awards and updated holdings. On 11/02/2025, he received 104,925 restricted stock units (RSUs) at $0 that vest in three equal installments beginning 11/02/2026. He also acquired 33,530 RSUs at $0 that vest in full on the earlier of June 3, 2026 or the 2026 annual meeting, subject to continued service.
Following the transactions, he beneficially owned 160,082 Class A shares directly. Indirect holdings were listed as 2,632,721 shares by TB 2024-2 GRAT and 2,632,721 shares by JB 2024-2 GRAT.
GoodRx Holdings (GDRX) director Scott Wagner filed a Form 4 reporting an award of 3,065 deferred stock units on 10/31/2025 at $0. Each unit represents a contingent right to one share of Class A common stock.
The units vest in substantially equal monthly installments beginning November 30, 2025 and ending December 31, 2025, and will settle upon the earliest of December 31, 2030, Separation from Service, a Change in Control, death, or Disability under the company’s director plan. Following the transaction, Wagner beneficially owned 185,269 shares directly and 182,900 shares indirectly via the Wagner Family Trust.
GoodRx Holdings announced that Co‑Chairman Trevor Bezdek ended his employment and executive officer service upon his employment agreement’s expiration on November 1, 2025, and will continue as a non‑employee Co‑Chairman of the Board.
As a non‑employee director, he will be eligible for the standard program: a $30,000 annual cash retainer for Board service, $10,000 for Nominating and Corporate Governance Committee service, and $75,000 for Co‑Chair of the Board, each pro‑rated for 2025. If serving on the Board as of the annual meeting date, he is also eligible for an annual RSU award valued at $230,000.
In connection with the transition, the Board granted RSUs valued at $420,000 (vesting one‑third annually over three years) and $134,219 (vesting in full on the earlier of June 3, 2026 or the 2026 Annual Meeting), effective November 2, 2025. The RSU share counts were determined using the 30‑day average closing price preceding the grant dates. He may defer cash retainers and RSU settlements under the Deferred Compensation Plan.
FAQ
What is the current stock price of Goodrx Holdings (GDRX)?
What is the market cap of Goodrx Holdings (GDRX)?
